Table 1.
Summary of studies measuring global cognition after TAVI using the MMSE.
| Study | n | Type of TAVI | Baseline | After procedure | 1-month F/U | 3-month F/U |
|---|---|---|---|---|---|---|
| Orvin et al., 2014 [8] | 36 | TF (MCV) = 31 TA (MCV) = 5 |
25.9 ± 3.3 | — | 27.6 ± 2.4 P < 0.001 |
— |
|
| ||||||
| Ghanem et al., 2013 [6] | 111 | TF (MCV) = 95 TF (ES) = 16 |
25.4 ± 3.4 | 25.4 ± 3.3a
25.1 ± 3.8b P = 0.58 |
— | — |
|
| ||||||
| Kahlert et al., 2012 [9] | 83 | Overall | 27.9 (27.5–28.3) |
27.7 (27.3–28.2) P = 0.521 |
— | 28.3 (28.0–28.7) P < 0.001 |
| TF (MCV) = 32 |
28.0
(27.5–28.5) |
27.7
(27.3–28.2) P = 0.488 |
— |
28.4
(27.9–28.9) P = 0.083 |
||
| TF (ES) = 26 |
27.3
(26.1–28.6) |
27.6
(26.4–28.7) P = 0.400 |
— |
28.1
(27.0–29.1) P = 0.003 |
||
| TA (ES) = 25 |
28.3
(27.8–28.8) |
28.0
(27.4–28.5) P = 0.256 |
— |
28.6
(28.1–29.0) P = 0.096 |
||
|
| ||||||
| Knipp et al., 2013 [10] | 27 | TA (ES) = 27 | Δ−0.72 ± 1.42c
P > 0.05 |
— | Δ0.95 ± 1.20c
P < 0.05 |
|
|
| ||||||
| Rodés-Cabau et al., 2011 [11] | 60 | TF (ES) = 29 TA (ES) = 31 |
28 (17–30) |
28 (16–30) P = 0.14 |
— | — |
|
| ||||||
| Kahlert et al., 2010 [12] | 32 | TF (MCV) = 10 | 28.9 (28.2–29.6) |
28.0 (27.0–29.0) P > 0.05 |
— | 28.9 (28.0–29.0) P > 0.05 |
| TF (ES) = 22 | 28.1 (26.7–29.5) |
28.3 (27.1–29.6) P > 0.05 |
28.1 (26.7–29.7) P > 0.05 |
|||
n = number, TAVI = transcatheter aortic valve implantation, MMSE = mini-mental status examination, TF = transfemoral, TA = transapical or transaxillary, ES = Edwards-SAPIEN, MCV = Medtronic CoreValve, and F/U = follow-up.
All studies were observational prospective cohort study. P values are for MMSE scores from the specified time-point compared to baseline unless otherwise stated. Normal score for MMSE is 24 or above.
aSubgroup with no risk of cognitive decline.
bSubgroup with risk of cognitive decline.
cChange in z-score after procedure to follow-up.